OneSource, Xbrane Partner for Global Biosimilar Supply
13 Jun 2025
2 Min Read
CW Team
OneSource Specialty Pharma Limited, a multi-modality specialty pharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic manufacturing partnership with Sweden-based Xbrane Biopharma AB (Nasdaq: XBRANE), a leading biotechnology firm. The collaboration will focus on the commercial production of Xbrane鈥檚 biosimilar portfolio.
Xbrane鈥檚 biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci鈥攁 biosimilar of ranibizumab鈥攈as already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.
Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource鈥檚 state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane鈥檚 global supply chain and enhancing the regulatory readiness of OneSource鈥檚 biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
As part of the collaboration, OneSource has also taken part in Xbrane鈥檚 most recent funding round, underlining the long-term strategic alignment between the two firms.
Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, 鈥淭he partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane鈥檚 proven success in biosimilar development, combined with OneSource鈥檚 fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world鈥檚 leading biotech companies.鈥�
Martin 脜mark, CEO of Xbrane Biopharma, added, 鈥淥ur partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.鈥�
The collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.
OneSource Specialty Pharma Limited, a multi-modality specialty pharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic manufacturing partnership with Sweden-based Xbrane Biopharma AB (Nasdaq: XBRANE), a leading biotechnology firm. The collaboration will focus on the commercial production of Xbrane鈥檚 biosimilar portfolio.Xbrane鈥檚 biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci鈥攁 biosimilar of ranibizumab鈥攈as already received market authorisation in Europe and was launched in 2023. The product is currently under regulatory review for entry into the United States market.Under the agreement, Xbrane will transfer the technology for selected biosimilars to OneSource鈥檚 state-of-the-art integrated Drug Substance and Drug Product (DS/DP) facility located in Bangalore, India. This move is aimed at bolstering Xbrane鈥檚 global supply chain and enhancing the regulatory readiness of OneSource鈥檚 biologics infrastructure. It is expected to accelerate approvals from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).As part of the collaboration, OneSource has also taken part in Xbrane鈥檚 most recent funding round, underlining the long-term strategic alignment between the two firms.Neeraj Sharma, Managing Director and CEO of OneSource Specialty Pharma, commented, 鈥淭he partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane鈥檚 proven success in biosimilar development, combined with OneSource鈥檚 fully integrated biologics platform, creates a strong foundation for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world鈥檚 leading biotech companies.鈥滿artin 脜mark, CEO of Xbrane Biopharma, added, 鈥淥ur partnership with OneSource gives us access to top-tier, cost-competitive manufacturing and expertise for our biosimilars. This is essential for our global competitiveness and our commitment to providing affordable medicines to patients and payers.鈥漈he collaboration is expected to enhance the reach of affordable biosimilar therapies globally, while also positioning OneSource as a leading biologics CDMO with strong regulatory and manufacturing capabilities.
Next Story
Reliance, Diehl Advance Pact for Precision-Guided Munitions
Diehl Defence CEO Helmut Rauch and Reliance Group鈥檚 Founder Chairman Anil D. Ambani have held discussions to advance their ongoing strategic partnership focused on Guided and Terminally Guided Munitions (TGM), under a cooperation agreement originally signed in 2019.This collaboration underscores Diehl Defence鈥檚 long-term commitment to the Indian market and its support for the Indian Government鈥檚 Make in India initiative. The partnership鈥檚 current emphasis is on the urgent supply of the Vulcano 155mm Precision Guided Munition system to the Indian Armed Forces.Simultaneously, the 鈥淰ulc..
Next Story
Modis Navnirman to Migrate to Main Board, Merge Subsidiary
Modis Navnirman Limited has announced that its Board of Directors has approved a key strategic initiative involving migration from the BSE SME platform to the Main Board of both BSE and NSE, alongside a merger with its wholly owned subsidiary, Shree Modis Navnirman Private Limited.The move to the main boards marks a major milestone in the company鈥檚 growth trajectory, reflecting its consistent financial performance, robust corporate governance, and long-term commitment to value creation. This transition will grant the company access to a broader investor base, improve market participation, en..
Next Story
Global Capital Flows Remain Subdued, EMEA Leads in Q1 2025
The Bharat InvITs Association鈥檚 industry update for Q1 2025 shows subdued global capital flows, with investment volumes remaining at the lower end of the five-year range despite a late 2024 recovery. According to data from Colliers and MSCI Real Capital Analytics, activity in North America declined slightly, while EMEA maintained steady levels and emerged as the top region for investment in standing assets.The EMEA region now hosts seven of the top ten cross-border capital destinations for standing assets, pushing the United States鈥� share of global activity below 15 per cent. Meanwhile, in..
